Answers are grounded in this paper and cite their sources.
To the Editor:Smith and Curnutte' give an excellent survey about the molecular basis of chronic granulomatous disease (CGD).Unfortunately, in a short clinical section the nitroblue tetrazolium (NBT) reduction assay is advised as the general method to diagnose this disease.However, "variant" CGD (with retained ability to produce some 0,) can be missed by the semiquantitative NBT slide test, with potentially hazardous consequences for the patient.
No takes yet. Share an insight, caveat, or question.
Roesler et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: